Lyra Therapeutics: Up on FDA feedback for sinus drug

Lyra Therapeutics

08/06/2021 23:03

** Shares of drug developer  LYRA.O  rise 13% to $8.90 in
extended trading
    ** Co reports positive outcome from End-Of-Phase 2 meeting
with U.S. FDA, for LYR-210, its lead candidate for treatment of
chronic rhinosinusitis, inflammatory disease of paranasal
sinuses (https://refini.tv/3gj0yOK)
    ** End-of-phase 2 meeting is undertaken to evaluate plan and
protocols of late-stage clinical program
    ** LYRA and FDA established key elements of late-stage
program to support a new drug application for LYR-210
    ** Based on FDA's suggestion, Lyra intends to enroll a total
of about 350 subjects in two concurrant late-stage trials
    ** Trial design provides opportunity to incorporate Chinese
sites, which could support approval in Asian territories - LYRA
    ** As of Tuesday's close, stock down ~31% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))